Rhenman & Partners Asset Management’s Regulus Therapeutics RGLS Stock Holding History

Rhenman & Partners Asset Management’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,107	Closed	-$97K	–	92
2018 Q3	$97K	Hold	4,107	–	–	0.01%	88
2018 Q2	$325K	Hold	4,107	–	–	0.03%	84
2018 Q1	$354K	Hold	4,107	–	–	0.04%	89
2017 Q4	$513K	Sell	4,107 -726	-15%	-$91.9K	0.07%	83
2017 Q3	$725K	Sell	4,833 -114	-2%	-$14.3K	0.09%	81
2017 Q2	$585K	Hold	4,947	–	–	0.08%	88
2017 Q1	$979K	Buy	4,947 +1,046	+27%	+$199K	0.16%	81
2016 Q4	$1.05M	Buy	3,901 +1,401	+56%	+$455K	0.2%	83
2016 Q3	$990K	Sell	2,500 -417	-14%	-$172K	0.16%	88
2016 Q2	$1.01M	Buy	2,917 +1,250	+75%	+$895K	0.18%	87
2016 Q1	$1.39M	Hold	1,667	–	–	0.28%	83
2015 Q4	$1.74M	Hold	1,667	–	–	0.26%	87
2015 Q3	$1.31M	Buy	+1,667	New	+$1.71M	0.21%	87

Other funds holding RGLS

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rhenman & Partners Asset Management's RGLS Position: Q4 2018 in Review

Rhenman & Partners Asset Management sold out of Regulus Therapeutics (RGLS) in Q4 2018, closing a stake of 4,107 shares — an estimated $97K sold.

Rhenman & Partners Asset Management first reported a position in RGLS in Q3 2015 and held it in 13 quarters. The position peaked at $1.74M in Q4 2015. 27 funds tracked by Wall St. Rank hold RGLS as of Q4 2018.

Rhenman & Partners Asset Management reported no remaining Regulus Therapeutics position as of Q4 2018 after selling out during the quarter.
Rhenman & Partners Asset Management sold 4,107 Regulus Therapeutics shares in Q4 2018, an estimated $97K.
Rhenman & Partners Asset Management first reported a position in Regulus Therapeutics in Q3 2015 and held it in 13 quarters.
Rhenman & Partners Asset Management's Regulus Therapeutics position peaked at $1.74M in Q4 2015.
27 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2018.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2018, filed 5 Feb 2019.